Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04, reports.
Brainstorm Cell Therapeutics Stock Performance
NASDAQ BCLI traded up $0.01 on Tuesday, reaching $0.96. The stock had a trading volume of 60,223 shares, compared to its average volume of 19,581. Brainstorm Cell Therapeutics has a 12-month low of $0.46 and a 12-month high of $1.69. The business’s 50-day moving average price is $0.91 and its 200 day moving average price is $0.86. The stock has a market cap of $14.22 million, a P/E ratio of -0.29 and a beta of 0.35.
About Brainstorm Cell Therapeutics
Read More
- Five stocks we like better than Brainstorm Cell Therapeutics
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
- Tyson Foods’ 10% Surge Puts a Breakout in Sight, But Wall Street Remains Cautious
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
